Chronic lymphocytic leukemia (CLL) patients diagnosed with severe acute respiratory syndrome coronavirus-2 disease (COVID-19) are at high risk of hospitalization and death independently of disease phase or treatment status. Considering these observations, we collected data from 21 CLL referral centers in Italy to better understand the attitude toward choice and management of venetoclax- based treatment during the pandemic, also in the light of ASH recommendations.